Fierce Biotech March 6, 2024
An analysis of real-world data by Abbott showed that the rise of GLP-1 medicines doesn’t necessarily have to take a major bite out of medtech sales, as combining the injections for diabetes and weight loss with continuous glucose monitors can help further improve blood sugar control.
In two studies of people with Type 2 diabetes taking GLP-1s, the addition of Abbott’s FreeStyle Libre CGM systems led to significant gains in HbA1C—regardless of the type of drug, how long patients took it, or whether they were also taking insulin, the company said.
Abbott claims that the real-time data provided by the CGM helps encourage users to stick to their diabetes treatment plans, while illustrating the effects of food intake, physical activity...
Today's Sponsors
Today's Sponsor